Alejandra Viviescas

Biologa y comunicadora científica— Biologist and science communicator

[Alejandra Viviescas @maalvima14]

A year ago today, I defended my PhD thesis, here are some thoughts about my life after the PhD as a science communicator https://t.co/UXvn3gl8zP

[Mariana Viviescas 🥑🐝🦄 @DedeVerde]

Se lo dedico a @maalvima14

[Alejandra Viviescas @maalvima14]

#UnaSolucionParaUberYa tener opciones de transporte por aplicativo es lo mejor para los consumidores

[Uber Colombia @Uber_Col]

😢Adiós... ojalá hasta pronto. #UnaSolucionParaUberYa

[Alejandra Viviescas @maalvima14]

@Brownianaweb A mi me ha servido para conectar con personas que eventualmente me han recomendado para trabajos

[Alejandra Viviescas @maalvima14]

Lab Model of Progressive #Fibrosis Allows Scientists to Evaluate #TherapeuticCandidates https://t.co/2AzWNjpvSu

[Alejandra Viviescas @maalvima14]

#Orencia Given FDA’s Breakthrough Status as Treatment to Prevent Graft-versus-Host Disease After #StemCellTransplant

#Lymphoma #BloodCancer https://t.co/qOR1hQQLIG

[Alejandra Viviescas @maalvima14]

FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer https://t.co/eQVf8APbv5

[Alejandra Viviescas @maalvima14]

3D Nerve Cell Models of #MultipleSclerosis, #ParkinsonsDisease Ready for Liftoff to Space Station for Long-term Study in Microgravity https://t.co/1bAUxW0plz

[Alejandra Viviescas @maalvima14]

Idebenone, an Approved Brain Stimulant, Could Prevent and Treat #PulmonaryFibrosis, Study Suggests https://t.co/v5K3Z4IAam

[Alejandra Viviescas @maalvima14]

Para quien está en Bogotá u otras ciudades de Colombia

[Alejandra Viviescas @maalvima14]

Aquestive Licenses #ALS Therapy #Riluzole Oral Film to Zambon in the European Union
#AmyotrophicLateralSclerosis
https://t.co/Jr4zeVgeeN

[Alejandra Viviescas @maalvima14]

FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL
#Lymphoma #tcell
https://t.co/gslfAc6h8Q

[Alejandra Viviescas @maalvima14]

Nektar Launches First-in-Human Trial Testing NKTR-255 in #Myeloma, #NonHodgkinLymphoma https://t.co/LGsswJpKVi

[Alejandra Viviescas @maalvima14]

Radicava Now Commercially Available in Canada, MTP-CA Announces
#ALS #AmyotrophicLateralSclerosis
https://t.co/q5QpRw4wT5

[Alejandra Viviescas @maalvima14]

Syros’ SY-5609 Shows Promising Anti Tumor Activity in #OvarianCancer Models, Among Others https://t.co/eF7S4IAluN

[Fundación Persea @FundacionPersea]

Estamos emocionados de lanzar nuestros productos de navidad. Para quienes lo estaban esperando: tarjetas, postales, mugs, bolsos y otros productos para desear: Merry Newtonmas!
Disponibles en varias tiendas online:

https://t.co/iFeYuYP7Hb

[Alejandra Viviescas @maalvima14]

@ospiNation Ospi, gracias por los boletines. Los seguí de cerca y aprendí bastante

[Alejandra Viviescas @maalvima14]

@bionewsservices launched a web site about #NeurotrophicKeratitis and I had the honor to write its first news piece. This was important on a personal level because, even though I do not have NK, I and know what it is to have eye damage laser surgery. https://t.co/e2TqITYsxJ

[Alejandra Viviescas @maalvima14]

SARM1 inhibitors are a potential oral treatment to slow disease progression in #neurodegenerativediseases like #multiplesclerosis, preclinical results suggest https://t.co/9CD3OZjFoQ

[Alejandra Viviescas @maalvima14]

Daiichi Sankyo Files New Drug Application for DS-8201 as Treatment for HER2-Positive #BreastCancer in Japan https://t.co/AaRUqZvbUx